SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors anticipate its optical interposer technology will be critical for next-generation AI data centers, fueled by strategic partnerships with industry giants like Luxshare and Foxconn that indirectly support hyperscalers like Meta and NVIDIA. The community is buzzing about POET's patented passive alignment process, which promises to revolutionize high-volume optical module manufacturing by enabling superior speed and energy efficiency over traditional copper. While eagerly awaiting official news, the market speculates on significant production orders ramping up by 2026, positioning POET as a potential leader in the rapidly expanding photonics sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving positive FDA feedback, which significantly de-risks the regulatory pathway for sonelokimab in hidradenitis suppurativa by allowing reliance on existing trial data for BLA submission. This development has fueled widespread community speculation around potential acquisition bids from major pharmaceutical companies like Merck and Eli Lilly, intensifying discussions about the drug's long-term value and multi-indication potential.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending amid strong market interest in edge computing solutions for the defense sector, recently bolstered by a new pre-production order from a major U.S. defense contractor. The community is buzzing with anticipation for a much larger situational awareness system contract, viewing the company as a key player in a rapidly expanding industry with a low share float.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending with significant bullish momentum, fueled by strong community sentiment surrounding its role in the U.S. critical minerals and battery recycling sector. Investors are actively discussing the impact of rising lithium prices and the company's strategic positioning amidst government initiatives like the G7 summit on critical metals, anticipating future growth and potential project milestones. Many believe ABAT is poised for substantial appreciation as demand for domestic battery materials heats up.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as geopolitical tensions, notably around Venezuela, fuel community debate over potential market volatility, with many anticipating a significant spike amidst broader economic concerns like debt and an AI bubble. Despite overall market resilience, traders are sharply divided, actively discussing hedging strategies and drawing parallels to past market crashes, even as others caution against the ETF's inherent decay.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to recent high-grade silver drill results and anticipation for an updated resource estimate in Q1 2026, alongside continued significant investment from Eric Sprott. The community is actively debating the company's vast undeveloped potential amidst a global silver shortage and increasing industrial demand, while also considering the speculative nature and potential for future dilution. This places HYMC at the forefront of discussions regarding domestic precious metal resources in a tightening market.

Lulu's Fashion Lounge Holdings, Inc. engages in providing an online website for clothing. It offers retailing of women's clothing, shoes, and accessories. The company was founded in 1996 and is headquartered in Chico, CA.

Lulus Fashion Lounge Holdings Inc

Lulu's Fashion Lounge Holdings (LVLU) is generating significant buzz and volume after Friedland Enterprises disclosed a substantial stake, pushing for immediate governance reforms. The community is heavily discussing Friedland's strong belief that the stock is profoundly undervalued compared to its peers, citing a considerable valuation gap. This activist involvement and proposed operational improvements are driving widespread speculation about the company's potential for a major re-rating and sustained price movement.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is trending after releasing strong preliminary fourth quarter and full-year 2025 results, which reported significant revenue growth and reaffirmed Adjusted EBITDA positivity. This announcement has ignited massive trading volume and a sharp increase in share price, leading to community discussion around a potential short squeeze and significant upside, alongside concerns about future dilution risks.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor (TSM) is trending due to reports of an impending US-Taiwan trade agreement that could significantly expand its manufacturing presence in Arizona, alongside robust revenue growth and optimistic analyst upgrades. The community is actively discussing TSM's critical role as the backbone of the AI sector, driven by surging chip demand and its strategic advancements in packaging capacity amid evolving geopolitical considerations.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending amidst an upcoming presentation at a major healthcare conference and recent UK approval for its COVID-19 vaccine, triggering milestone payments. Community discussions are highly active around a significant trade secret lawsuit and mixed interim data for its cystic fibrosis therapy, with many believing the company is fundamentally undervalued and a potential acquisition target for its mRNA platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MannKind (NASDAQ:MNKD) Insider Stuart Tross Sells 47,006 Shares

MannKind Corporation (NASDAQ:MNKD - Get Free Report) insider Stuart Tross sold 47,006 shares of the company's stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an...

<ul class="summary-bullets"><li>MannKind is now eyeing a potential approval of its Afrezza inhalation powder for children and adolescents living with type 1 or type 2 diabetes.</li><li>H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update.</li><li>The firm said it is positive on MannKind's outlook over the next two years, saying "very little value is ascribed to the multiple tailwinds that could be validated in 2026."</li></ul>MannKind Corporation (MNKD) on Thursday said that it expects two high potential launches going into 2026, driving investor optimism and sending shares up 2%.&nbsp; “With two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation,” CEO Michael Castagna<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/08/3215359/29517/en/MannKind-Provides-Business-Updates-and-2026-Growth-Drivers.html"> said,</a> while adding that the company closed 2025 “on a high note” with its acquisition of scPharmaceuticals.<h2 class="st-heading-2">MannKind’s Potential Launches</h2>MannKind is now eyeing a potential approval of its Afrezza inhalation powder for children and adolescents living with type 1 or type 2 diabetes. The U.S. Food and Drug Administration is expected to rule on the application by May 29 and if approved, it would be the first needle-free insulin option for pediatric patients in over 100 years of insulin therapy, the company said.The company is also eyeing approval for its FUROSCIX ReadyFlow Autoinjector, developed to deliver a subcutaneous furosemide injection in under 10 seconds as an investigational alternative to the FDA-approved FUROSCIX On-body Infusor. Furosemide is used for treatment of edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD).<h2 class="st-heading-2">Analyst Weighs In</h2>H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update. The price target represents a potential upside of about 88% from the stock's closing price on Wednesday.&nbsp;The firm said it is positive on MannKind's outlook over the next two years, saying "very little value is ascribed to the multiple tailwinds that could be validated in 2026."<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MNKD shares jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user dismissed the company’s Thursday update as “another pump and dump.”<stembedurl>https://www.stocktwits.com/Kool_Aid_Mann/message/641251643</stembedurl><a href="https://stocktwits.com/symbol/MNKD">MNKD stock</a> has dropped 3% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ford-stock-rallies-on-piper-sandler-upgrade-plans-to-launch-autonomous-driving-on-30000-ev/cmUbiTNR45X">Ford Stock Rallies On Piper Sandler Upgrade, Plans To Launch Autonomous Driving On $30,000 EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026

The company’s CEO Michael Castagna said that with two high-potential launches on the horizon, 2026 is shaping up to be a catalyst-rich year that positions MannKind for long-term value creation. 

Equity

MannKind (NASDAQ:MNKD) Reaches New 52-Week High - What's Next?

MannKind (NASDAQ:MNKD) Hits New 12-Month High - Here's Why...

Voya Investment Management LLC Sells 480,182 Shares of MannKind Corporation $MNKD

Voya Investment Management LLC cut its holdings in MannKind Corporation (NASDAQ:MNKD - Free Report) by 89.7% in the third quarter, according to its most recent Form 13F filing with the Securities and...

Calamos Advisors LLC Acquires New Position in MannKind Corporation $MNKD

Calamos Advisors LLC acquired a new stake in shares of MannKind Corporation (NASDAQ:MNKD - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange...

180 Wealth Advisors LLC Increases Stock Position in MannKind Corporation $MNKD

180 Wealth Advisors LLC lifted its position in shares of MannKind Corporation (NASDAQ:MNKD - Free Report) by 11.2% during the third quarter, according to the company in its most recent filing with...

MannKind (NASDAQ:MNKD) Share Price Passes Above Two Hundred Day Moving Average - Here's Why

MannKind (NASDAQ:MNKD) Stock Passes Above Two Hundred Day Moving Average - Here's What Happened...

Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?

Key PointsCEO Michael Castagna sold 65,804 shares on Dec. 17, 2025, for a total value of approximately ~$395,482 at a weighted average price around $6.01 per share...

<ul class="summary-bullets"><li>The FDA expanded Furoscix use to certain pediatric patients.</li><li>MannKind received five new U.S. patents supporting its ReadyFlow autoinjector, which is still under FDA review.</li><li>The FDA is expected to decide on the ReadyFlow application by July 26, 2026.</li></ul>MannKind Corp (MNKD) shares fell on Tuesday even as the company announced regulatory and patent updates tied to its&nbsp;Furoscix drug, which is used to treat fluid buildup in people with heart failure and kidney disease.At the time of writing, the stock fell 1.4% to $5.91.<h2 class="st-heading-2">Furoscix Gets Pediatric Approval</h2>The company said the U.S. Food and Drug Administration (FDA) approved wider use of&nbsp;Furoscix to include certain pediatric patients who weigh at least 43 kilograms. The drug was previously approved only for adults with fluid buildup caused by chronic heart failure or chronic kidney disease.The company’s chief medical officer said the approval makes&nbsp;Furoscix available to a limited pediatric group and provides an option for treatment outside the hospital for patients who meet the weight requirement.<h2 class="st-heading-2">Patents Support ReadyFlow Autoinjector</h2>MannKind also said it received five new U.S. patents related to its ReadyFlow autoinjector, a device under FDA review that is designed to deliver furosemide in seconds rather than hours.The patents cover the drug formulation and methods of treatment and could provide protection through 2040 if the product is approved. The company said the patents would be listed in the FDA’s Orange Book upon approval.ReadyFlow is based on technology developed by scPharmaceuticals, which MannKind acquired in August. Before the acquisition, scPharmaceuticals reported positive study results showing that the autoinjector delivered furosemide at levels comparable to intravenous dosing. In that study, patients had similar fluid removal results to IV treatment, reported little to no injection pain, and experienced side effects consistent with standard furosemide use.The company reiterated that the FDA is reviewing its application for ReadyFlow for use in adults with heart failure or kidney disease, with a decision expected by July 26, 2026.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for MannKind was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:970/141;" src="https://news.stocktwits-cdn.com/mnkd_ss_png_2d06a45896.webp" alt="mnkd ss.png" width="970" height="141"><figcaption>MNKD sentiment and message volume as of December 23| Source: Stocktwits</figcaption></figure>One user said the pediatric approval carries limited commercial impact but signals regulatory comfort with&nbsp;Furoscix, which could be supportive ahead of the FDA’s July 2026 decision on the ReadyFlow autoinjector.<stembedurl>https://stocktwits.com/kevinmik/message/639971814</stembedurl>Another retail investor questioned the timing of the announcement, noting it was released just ahead of the Christmas holiday when market activity is typically thin.<stembedurl>https://stocktwits.com/ChillyMutt/message/639959660</stembedurl><a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined 0.9% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MannKind’s stock has declined 0.9% so far in 2025. (Photo credit: Getty Images)

MannKind Stock Slips Despite FDA Clearing Pediatric Use Of Heart Failure Drug — What’s Spooking Investors?

Shares fell as investors flagged limited commercial impact from the pediatric approval and questioned the timing of the announcement during thin holiday trading.

Michael Castagna Sells 65,804 Shares of MannKind (NASDAQ:MNKD) Stock

MannKind Corporation (NASDAQ:MNKD - Get Free Report) CEO Michael Castagna sold 65,804 shares of the business's stock in a transaction that occurred on Wednesday, December 17th. The shares were sold...

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$5.85
Prev Close	$5.85
Open	$5.82
Dividend Yield	0.00%
50-Day Moving Average	$5.59
Beta	0.87
Avg. Volume	3.39M
PE Ratio	61.19

52-Week High	$6.51
52-Week Low	$3.38
Market Capitalization	$1.8B
EPS (Annual)	$0.0972
Price to Book	-39.76
Revenue Per Employee	$701,484.03
Enterprise Value/EBITDA	N/A

MNKD
Mannkind Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MNKD News

MNKDMannkind Corp